CN

CN
News
News
News
Always Share with You
Every Bit of Our Progress
Home > News > Details
VitaFlow Liberty® Flex Transcatheter Aortic Valve Implantation System Receives Market Approval from NMPA
2024-12-21
Back

Shanghai, China, 07 January 2025 — MicroPort® CardioFlow recently announced that its VitaFlow Liberty® Flex Transcatheter Aortic Valve Implantation System (“VitaFlow Liberty® Flex”) has received market approval from the National Medical Products Administration (NMPA) of the People’s Republic of China (Approval No. 20243032595). As the third generation transcatheter aortic valve implantation (TAVI) product from MicroPort® CardioFlow, VitaFlow Liberty® Flex delivers advanced medical solutions for the treatment of structural heart diseases, further benefiting physicians and patients in China.

 

VitaFlow Liberty® Flex is the world’s only coaxial steering, self-expanding TAVI delivery system, and the first retrievable motorized TAVI delivery system. It features the innovative X3 Flexis™ 3D steering function for smoother and safer navigation over the aortic arch and valve, ensuring better coaxial alignment results. A shorter steering segment, positioned closer to the stent, enhances adaptability to the patient’s aortic anatomy. The inner tube steering technology maintains precise coaxial alignment during valve deployment, ensuring more stable and precise implantation. The system also includes a commissural alignment feature that preserves coronary access and leaves room for future coronary intervention. The delivery system is made of composite flexible materials to provide smoother navigation and reduce vascular complications. Additionally, the smart limit switch design incorporates intelligent braking during deployment, with audible and visual alarms to improve safety and enhance physician confidence during the procedure.

 

Mr. Jeff Lindstrom, President of MicroPort® CardioFlow, commented: "The VitaFlow Liberty® Flex will further enhance procedural efficiency and safety while significantly reducing surgical complications. It empowers physicians with enhanced usability while delivering higher-quality care to patients."

 

Mr. Guoming Chen, Chairman of MicroPort® CardioFlow, remarked: "With over 15 years of commitment to the TAVI field, our VitaFlow® series TAVI product has treated more than 10,000 patients with aortic valve disease and earned high praise from international experts. The launch of VitaFlow Liberty® Flex brings cutting-edge innovative technologies to address more complex procedural scenarios and achieve superior clinical outcomes."

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.


CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

×
TOP

©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号

互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.